


22 February 2021 Sydney, Australia

# Nyrada Reports Half Year FY2021 Results

**Highlights:**

- Increased investment in R&D of $1.05m (1HFY20: $0.66m) to advance two lead drug development programs
- Corporate and administration expenses of $0.56m increased modestly (1HFY20: $0.46m) to support program expansion and operations as a newly listed company
- Strong cash position of $4.06m to advance towards Phase 1 human clinical trials, due to judicious capital deployment
    - Includes $1.08m R&D tax incentive for FY19 received in 1HFY21
- Cholesterol-Lowering Program: 57% reduction in total cholesterol reported in efficacy study; on track to commence human clinical trials at the end of CY 2021
- Brain Injury Program: achieved durable therapeutic levels and finalised collaboration agreement with Walter Reed and UNSW Sydney with non-dilutive funding opportunities

**Sydney, 22 February 2021:** Nyrada Inc (ASX: NYR), a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today released its Financial Report for the half year ended 31 December 2020, along with an update on the Company's two lead drug development programs.

Looking ahead, Nyrada will continue to advance its Brain Injury and Cholesterol-Lowering Programs towards Phase 1 human trials.

**Commenting on the Company's outlook, CEO James Bonnar said**, "The half-year has delivered some exceptional results and we are very pleased with the progress in our Cholesterol-Lowering and Brain Injury programs. Of particular note is our new collaboration with the highly regarded Walter Reed Army Institute of Research and UNSW Sydney. This collaboration validates the potential of our brain injury drug candidates and we expect to report results from the studies over the coming 12 months.

"We are equally encouraged with the progress in our Cholesterol-Lowering program as we confidently prepare to commence Phase 1 human clinical trials. As part of these preparations, we will be conducting an *in vivo* efficacy study to assess the optimal dose of NYX-PCSK9i and expect to report the results in mid-2021."



## Programs Update

### Cholesterol-Lowering Program

During the half-year, Nyrada continued to test the safety and efficacy of the Company's cholesterol-lowering preclinical candidate, NYX-PCSK9i. Importantly, Nyrada demonstrated equivalency between NYX-PCSK9i and the two FDA approved monoclonal PCSK9 antibody drugs, alirocumab (Praluent®, Sanofi/Regeneron) and evolocumab (Repatha®, Amgen).

Nyrada also demonstrated a 57% reduction in total cholesterol from NYX-PCSK9i in an efficacy study of the compound in a specialised mouse model, which possesses human-like characteristics with respect to cardiovascular health. In all preclinical studies undertaken during the half year, NYX-PCSK9i was well tolerated and no adverse effects were observed.

### Brain Injury Program

During the half year, Nyrada continued to progress and improve the drug-like characteristics of its drug candidates. In July 2020, Nyrada achieved durable therapeutic levels in two compounds that were safe and well tolerated following a 6-hour, continuous intravenous infusion, the preferred route for patients suffering from moderate-severe traumatic brain injury (TBI) and stroke.

Nyrada also improved the solubility and tissue protein-binding properties in new drug analogues, while maintaining potency in blocking calcium ion build up in cells, which would otherwise activate cell-death pathways and inflammation in the brain following TBI. These improvements are assisting the optimisation of the final lead molecule for preclinical and clinical studies.

### About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

www.nyrada.com

*Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.*

**Investor & Corporate Enquiries:**
Laura Vize
Investor Relations Manager
T: 0417 026 056
E: info@nyrada.com

**Company Secretary:**
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au



**Media Enquiries:**
Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

**Forward-Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.